Fludarabine, Mitoxantrone And Zevalin Produces 96% Complete Remission Rate In First-line Treatment Of Patients With Follicular non-Hodgkin's Lymphoma

This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.

Cell Therapeutics, Inc. (CTI) announced that patients with previously untreated follicular non-Hodgkin's lymphoma (NHL) treated with fludarabine and mitoxantrone, followed by administration of Zevalin(R) (Ibritumomab Tiuxetan), achieved 96 percent complete remission (CR), an estimated three-year progression-free survival (PFS) rate of 76 percent, and a 100 percent estimated three-year overall survival (OS) rate.

 

0 Comments

You must be logged in to post comments.

We care about your feedback. Let us know how we can improve your CancerCompass experience.